RxDoctor Payments Data

Beverly Patterson

Nurse Practitioner · Newport News, VANPI 1124146626

Payments from drug & device makers

$4,203in general payments, 2019–2025

Across 217 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biocryst US Sales Co., LLC$782
  • Regeneron Healthcare Solutions, Inc.$774
  • Sanofi$639
  • CSL Behring$503
  • GSK$413
  • Takeda Pharmaceuticals U.S.A., Inc.$227
  • plus $865 from 21 others

What the payments were for

  • Food & beverage$4,16799%
  • Education$60%
  • Other$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,203 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$229,453
Medicare patients
1,095
Services billed
3,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrladeyoBerotralstat Hydrochloride12$481,952
XolairOmalizumab12$99,717
Dupixent SyringeDupilumab12$44,904
Azelastine Hcl235$5,213
Fluticasone Propionate344$3,795
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth37$3,508
RyaltrisOlopatadine Hcl/Mometasone14$3,424
Epinephrine13$2,025
Ipratropium Bromide27$1,523
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav116$1,348
Budesonide11$1,294
Azelastine-FluticasoneAzelastine/Fluticasone13$1,124
Montelukast Sodium114$1,050
Wixela InhubFluticasone Propion/Salmeterol25$867
Levocetirizine Dihydrochloride71$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Biocryst US Sales Co., LLCOrladeyo$782$481,95212 claims
Hikma Pharmaceuticals USARyaltris, Epinephrine$33$5,44927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →